Atria Investments Inc Decreases Holdings in Illumina, Inc. (NASDAQ:ILMN)

Atria Investments Inc decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,093 shares of the life sciences company’s stock after selling 424 shares during the period. Atria Investments Inc’s holdings in Illumina were worth $2,551,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ILMN. WCM Investment Management LLC lifted its position in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. ARK Investment Management LLC purchased a new stake in Illumina during the fourth quarter valued at approximately $91,714,000. Massachusetts Financial Services Co. MA increased its stake in Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after purchasing an additional 631,294 shares in the last quarter. Janus Henderson Group PLC increased its stake in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Illumina by 116.9% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after purchasing an additional 466,519 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Guggenheim cut their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $100.00 in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Stock Performance

ILMN opened at $86.62 on Monday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market cap of $13.72 billion, a price-to-earnings ratio of -11.28, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The firm’s fifty day simple moving average is $118.38 and its two-hundred day simple moving average is $131.48.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.